Crispr Therapeutics shares tumble after significant earnings miss
Director Gene Salkind of Upexi, INC. (OTC:UPXI) recently purchased 20,243 shares of common stock at $4.94, for a total transaction value of $100,000. The purchase comes as the stock shows strong momentum, with a 54.7% gain year-to-date, though trading at $4.88 currently, down from its 52-week high of $22.57. According to InvestingPro analysis, the stock appears overvalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction occurred on July 11, 2025. The filing also indicates that Salkind acquired an additional 200,000 shares of Upexi common stock on July 16, 2025, as part of the Issuer’s Equity Incentive Plan. 50,000 shares vest in full 90 days from July 1, 2025, and 150,000 shares vest quarterly in equal installments over 12 months beginning July 1, 2025. With a market capitalization of $243.58 million, Upexi shows mixed signals, including 15 key insights available on InvestingPro, which provides comprehensive analysis through its Pro Research Report.
In other recent news, Upexi Inc. has made significant financial moves, starting with a $500 million equity line agreement with A.G.P./Alliance Global Partners (NYSE:GLP). This agreement allows Upexi to sell its common stock at its discretion, providing the company with enhanced financial flexibility. The proceeds from this agreement are intended for general corporate purposes and to advance Upexi’s Solana cryptocurrency treasury strategy. In a related development, Upexi acquired an additional 83,000 Solana (SOL) tokens for $16.7 million, increasing its cryptocurrency holdings to 1.9 million SOL tokens, valued at approximately $381 million. Furthermore, the company recently purchased 100,000 SOL tokens for $17.7 million, bringing its total holdings to 1,818,809 SOL, valued at around $331 million. This purchase follows Upexi’s successful closing of a $200 million equity and convertible notes private placement. The company’s strategic moves in expanding its Solana holdings are aimed at enhancing its staking revenue potential. These developments highlight Upexi’s ongoing efforts to strengthen its financial position and cryptocurrency strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.